OTCMKTS:BNOEF Bionomics - BNOEF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. $0.02 0.00 (0.00%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0452-Week Range$0.01▼$0.07VolumeN/AAverage Volume21,030 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlinesShort Interest About Bionomics (OTCMKTS:BNOEF) StockBionomics Ltd. is a clinical stage biopharmaceutical company. It engages in the development of novel drug candidates focused on the treatment of serious central nervous system disorders. The company was founded in 1996 and is headquartered in Eastwood, Australia.Read More Receive BNOEF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address BNOEF Stock News HeadlinesDecember 15, 2022 | marketwatch.comBionomics Names Spyridon Papapetropoulos as President, CEODecember 15, 2022 | finance.yahoo.comBionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive OfficerFebruary 4, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! November 21, 2022 | nz.finance.yahoo.comBionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United StatesNovember 17, 2022 | marketwatch.comBionomics Shares Drop 18% After ADS Offering PricesOctober 18, 2022 | seekingalpha.comBionomics receives R&D tax incentive refund for FY22 of A$4.6MSeptember 21, 2022 | technews.tmcnet.comBionomics to Host KOL Webinar on BNC210 and Social Anxiety DisorderJanuary 3, 2022 | marketwatch.comBionomics Phase 2 Study for Social Anxiety BeginsFebruary 4, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 26, 2021 | nasdaq.comBionomics Ltd. - ADR Shares Near 52-Week Low - Market MoverNovember 24, 2021 | markets.businessinsider.comAustralian biotech Bionomics files for IPO with plans to list on NasdaqNovember 23, 2021 | finance.yahoo.comBionomics Files Registration Statement for Proposed Initial Public Offering in the United StatesSeptember 24, 2021 | fool.com.auThese 3 ASX Healthcare shares have soared over 10% today - The Motley Fool AustraliaSeptember 13, 2021 | streetinsider.comNovamind to Serve as Research Site for Karuna Therapeutics Late-Stage Clinical Trial - StreetInsider.comJuly 30, 2021 | finance.yahoo.comCyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update - Yahoo FinanceJuly 9, 2021 | finance.yahoo.comNovamind Selected as Research Site for Bionomics' PTSD Clinical Trial - Yahoo FinanceJuly 6, 2021 | finance.yahoo.comBionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSDMay 12, 2021 | seekingalpha.comBionomics Finds A Second Bow To Its Antianxiety Drug BNC210May 10, 2021 | finance.yahoo.comBionomics BNC210 Expansion into Social Anxiety DisorderApril 13, 2021 | finance.yahoo.comNovamind Increases Strategic Investment in BionomicsMarch 8, 2021 | msn.comUp almost 1000% in 1 year, the Bionomics (ASX:BNO) share price moves higherFebruary 27, 2021 | proactiveinvestors.com.auBionomics' positive pharmacokinetic results confirms it can begin second Phase 2 study to treat PTSDFebruary 26, 2021 | proactiveinvestors.comBionomics' positive pharmacokinec results confirms it can begin second Phase 2 study to treat PTSDFebruary 14, 2021 | seekingalpha.comBionomics Springs Back To LifeFebruary 11, 2021 | finance.yahoo.comNovamind Announces Strategic Investment in Bionomics to Support PTSD Clinical TrialFebruary 10, 2021 | finance.yahoo.com$16 Million Capital Raise to Progress Bionomics BNC210 PTSD TrialFebruary 9, 2021 | fool.com.auWhy the Bionomics (ASX:BNO) share price is climbing todaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BNOEF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address BNOEF Company Calendar Today2/04/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Noncommercial research organizations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BNOEF CUSIPN/A CIKN/A Webwww.bionomics.com.au Phone(188) 150-7400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.58 Key ExecutivesSpyros PapapetropoulosPresident, Chief Executive Officer & DirectorAdrian HintonChief Financial OfficerLiz DoolinVice President-Clinical DevelopmentConnor BernsteinVice President-Strategy & Corporate DevelopmentSuzanne Grace IrwinSecretaryKey Competitors[email protected] TechnologyOTCMKTS:LPTC111NASDAQ:YI1933 IndustriesOTCMKTS:TGIFF3SBioOTCMKTS:TRSBF4Front VenturesOTCMKTS:FFNTFView All Competitors BNOEF Stock - Frequently Asked Questions How have BNOEF shares performed in 2023? Bionomics' stock was trading at $0.0360 at the beginning of 2023. Since then, BNOEF stock has decreased by 34.0% and is now trading at $0.0238. View the best growth stocks for 2023 here. Are investors shorting Bionomics? Bionomics saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 37,800 shares, a decrease of 67.6% from the December 31st total of 116,500 shares. Based on an average daily trading volume, of 326,600 shares, the short-interest ratio is currently 0.1 days. View Bionomics' Short Interest. What is Bionomics' stock symbol? Bionomics trades on the OTCMKTS under the ticker symbol "BNOEF." How do I buy shares of Bionomics? Shares of BNOEF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bionomics' stock price today? One share of BNOEF stock can currently be purchased for approximately $0.02. How can I contact Bionomics? The official website for the company is www.bionomics.com.au. The company can be reached via phone at (188) 150-7400. This page (OTCMKTS:BNOEF) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.